Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 2
1996 1
1997 1
2000 1
2002 1
2008 1
2012 1
2013 2
2014 2
2015 1
2016 1
2017 1
2018 3
2019 1
2020 1
2021 3
2022 1
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
Klinghammer K, Gauler T, Dietz A, Grünwald V, Stöhlmacher J, Knipping S, Schroeder M, Guntinas-Lichius O, Frickhofen N, Lindeman HW, Fietkau R, Haxel B, Große-Thie C, Maschmeyer G, Zipfel M, Martus P, Knoedler M, Keilholz U. Klinghammer K, et al. Among authors: zipfel m. Eur J Cancer. 2019 Nov;122:53-60. doi: 10.1016/j.ejca.2019.08.018. Epub 2019 Oct 13. Eur J Cancer. 2019. PMID: 31618704 Clinical Trial.
Cross-sectional increase of adherence to multidisciplinary tumor board decisions.
Hollunder S, Herrlinger U, Zipfel M, Schmolders J, Janzen V, Thiesler T, Güresir E, Schröck A, Far F, Pietsch T, Pantelis D, Thomas D, Vornholt S, Ernstmann N, Manser T, Neumann M, Funke B, Schmidt-Wolf IGH. Hollunder S, et al. Among authors: zipfel m. BMC Cancer. 2018 Sep 29;18(1):936. doi: 10.1186/s12885-018-4841-4. BMC Cancer. 2018. PMID: 30268109 Free PMC article.
Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
Goerling U, Gauler T, Dietz A, Grünwald V, Knipping S, Guntinas-Lichius O, Frickhofen N, Lindeman HW, Fietkau R, Haxel B, Große-Thie C, Maschmeyer G, Zipfel M, Martus P, Knoedler M, Keilholz U, Klinghammer K. Goerling U, et al. Among authors: zipfel m. Oncol Res Treat. 2022;45(6):319-325. doi: 10.1159/000521415. Epub 2021 Dec 10. Oncol Res Treat. 2022. PMID: 34915492 Free article. Clinical Trial.
Lung cancer screening with MRI: results of the first screening round.
Meier-Schroers M, Homsi R, Skowasch D, Buermann J, Zipfel M, Schild HH, Thomas D. Meier-Schroers M, et al. Among authors: zipfel m. J Cancer Res Clin Oncol. 2018 Jan;144(1):117-125. doi: 10.1007/s00432-017-2521-4. Epub 2017 Sep 20. J Cancer Res Clin Oncol. 2018. PMID: 28932985
21 results